Treatment of osteoporosis: role of bone-forming agents.
Reginster
J Y
JY
WHO Collaborating Center for Public Health Aspects of Osteo-Articular Diseases, University of Liège, Liège, Belgium.
Halkin
V
V
Henrotin
Y
Y
Gosset
C
C
D045930:Anabolic Agents / Q000627:therapeutic use*; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D005459:Fluorides / Q000627:therapeutic use; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000627:therapeutic use; D013002:Somatomedins / Q000627:therapeutic use; D013324:Strontium / Q000627:therapeutic use
D045930:Anabolic Agents; D010281:Parathyroid Hormone; D013002:Somatomedins; D013006:Growth Hormone; D005459:Fluorides; D013324:Strontium